Literature DB >> 16123218

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

Kai Fu1, Dennis D Weisenburger, Timothy C Greiner, Sandeep Dave, George Wright, Andreas Rosenwald, Michael Chiorazzi, Javeed Iqbal, Stefan Gesk, Reiner Siebert, Daphne De Jong, Elaine S Jaffe, Wyndham H Wilson, Jan Delabie, German Ott, Bhavana J Dave, Warren G Sanger, Lynette M Smith, Lisa Rimsza, Rita M Braziel, H Konrad Müller-Hermelink, Elias Campo, Randy D Gascoyne, Louis M Staudt, Wing C Chan.   

Abstract

Cyclin D1 overexpression is believed to be essential in the pathogenesis of mantle cell lymphoma (MCL). Hence, the existence of cyclin D1-negative MCL has been controversial and difficult to substantiate. Our previous gene expression profiling study identified several cases that lacked cyclin D1 expression, but had a gene expression signature typical of MCL. Herein, we report the clinical, pathologic, and genetic features of 6 cases of cyclin D1-negative MCL. All 6 cases exhibited the characteristic morphologic features and the unique gene expression signature of MCL but lacked the t(11;14)(q13; q32) by fluorescence in situ hybridization (FISH) analysis. The tumor cells also failed to express cyclin D1 protein, but instead expressed either cyclin D2 (2 cases) or cyclin D3 (4 cases). There was good correlation between cyclin D protein expression and the corresponding mRNA expression levels by gene expression analysis. Using interphase FISH, we did not detect chromosomal translocations or amplifications involving CCND2 and CCND3 loci in these cases. Patients with cyclin D1-negative MCL were similar clinically to those with cyclin D1-positive MCL. In conclusion, cases of cyclin D1-negative MCL do exist and are part of the spectrum of MCL. Up-regulation of cyclin D2 or D3 may substitute for cyclin D1 in the pathogenesis of MCL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123218      PMCID: PMC1895253          DOI: 10.1182/blood-2005-04-1753

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.

Authors:  P M Banks; J Chan; M L Cleary; G Delsol; C De Wolf-Peeters; K Gatter; T M Grogan; N L Harris; P G Isaacson; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

3.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.

Authors:  R Chiarle; L M Budel; J Skolnik; G Frizzera; M Chilosi; A Corato; G Pizzolo; J Magidson; A Montagnoli; M Pagano; B Maes; C De Wolf-Peeters; G Inghirami
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

4.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.

Authors:  C L Rosenberg; E Wong; E M Petty; A E Bale; Y Tsujimoto; N L Harris; A Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

5.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

6.  Genomic organization, chromosomal localization, and independent expression of human cyclin D genes.

Authors:  T Inaba; H Matsushime; M Valentine; M F Roussel; C J Sherr; A T Look
Journal:  Genomics       Date:  1992-07       Impact factor: 5.736

7.  Identification of G1 kinase activity for cdk6, a novel cyclin D partner.

Authors:  M Meyerson; E Harlow
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

8.  D-type cyclin-dependent kinase activity in mammalian cells.

Authors:  H Matsushime; D E Quelle; S A Shurtleff; M Shibuya; C J Sherr; J Y Kato
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

9.  Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody.

Authors:  Wah Cheuk; Kathy O Y Wong; Cesar S C Wong; John K C Chan
Journal:  Am J Surg Pathol       Date:  2004-06       Impact factor: 6.394

10.  Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation.

Authors:  S Mittnacht; J A Lees; D Desai; E Harlow; D O Morgan; R A Weinberg
Journal:  EMBO J       Date:  1994-01-01       Impact factor: 11.598

View more
  73 in total

1.  Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.

Authors:  Javeed Iqbal; Yulei Shen; Yanyan Liu; Kai Fu; Elaine S Jaffe; Cuiling Liu; Zhongfeng Liu; Cynthia M Lachel; Karen Deffenbacher; Timothy C Greiner; Julie M Vose; Sharathkumar Bhagavathi; Louis M Staudt; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Timothy W McKeithan; Wing C Chan
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

Review 2.  New molecular targets in mantle cell lymphoma.

Authors:  Samir Parekh; Marc A Weniger; Adrian Wiestner
Journal:  Semin Cancer Biol       Date:  2011-09-18       Impact factor: 15.707

3.  A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma.

Authors:  Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet
Journal:  Virchows Arch       Date:  2010-04-24       Impact factor: 4.064

4.  All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma.

Authors:  Amareshwar T K Singh; Andrew M Evens; Reilly J Anderson; Jennifer A Beckstead; Natesan Sankar; Antonella Sassano; Savita Bhalla; Shuo Yang; Leonidas C Platanias; Trudy M Forte; Robert O Ryan; Leo I Gordon
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

5.  ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.

Authors:  Zheng Chen; Albert E Teo; Nami McCarty
Journal:  Clin Cancer Res       Date:  2015-09-08       Impact factor: 12.531

Review 6.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

7.  CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.

Authors:  Itziar Salaverria; Cristina Royo; Alejandra Carvajal-Cuenca; Guillem Clot; Alba Navarro; Alejandra Valera; Joo Y Song; Renata Woroniecka; Grzegorz Rymkiewicz; Wolfram Klapper; Elena M Hartmann; Pierre Sujobert; Iwona Wlodarska; Judith A Ferry; Philippe Gaulard; German Ott; Andreas Rosenwald; Armando Lopez-Guillermo; Leticia Quintanilla-Martinez; Nancy L Harris; Elaine S Jaffe; Reiner Siebert; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2012-12-18       Impact factor: 22.113

Review 8.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

9.  Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.

Authors:  Dong Chen; Mark E Law; Jason D Theis; Jeffrey D Gamez; Lynn B Caron; Julie A Vrana; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

10.  Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR.

Authors:  Leticia Quintanilla-Martinez; Julia Slotta-Huspenina; Ina Koch; Margit Klier; Eric D Hsi; Laurence de Leval; Wolfram Klapper; Stefan Gesk; Reiner Siebert; Falko Fend
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.